VX-702 50mg 50mg | Purity Not Available
Adooq Bioscience
VX-702 is an orally bioavailable inhibitor of p38 MAP kinase that inhibits platelet agonist induced p38 activation (IC50= 4 to 20 nM).
More Information Supplier PageSearch Results
VX-702 200mg 200mg | Purity Not Available
Adooq Bioscience
VX-702 is an orally bioavailable inhibitor of p38 MAP kinase that inhibits platelet agonist induced p38 activation (IC50= 4 to 20 nM).
More Information Supplier PageVX-702 100mg 100mg | Purity Not Available
Adooq Bioscience
VX-702 is an orally bioavailable inhibitor of p38 MAP kinase that inhibits platelet agonist induced p38 activation (IC50= 4 to 20 nM).
More Information Supplier PageVX-765 100mg 100mg | Purity Not Available
Adooq Bioscience
VX-765 is a novel Caspase-1 inhibitor,which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18.
More Information Supplier PageVX-765 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
VX-765 is a novel Caspase-1 inhibitor,which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18.
More Information Supplier PageVX-809 25mg 25mg | Purity Not Available
Adooq Bioscience
VX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-809 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
VX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-809 10mg 10mg | Purity Not Available
Adooq Bioscience
VX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier Page